key: cord-0721610-mexw7uhf
authors: Chen, Yi-Ching; Kung, Yu-An; Janapatla, Rajendra-Prasad; Hsu, Mei-Hua; Lien, Reyin; Chen, Jeng-Chang; Shih, Shin-Ru; Chiu, Cheng-Hsun
title: Neutralization antibody titers against SARS-CoV-2 in an infant born to a mother with COVID-19 Placental transfer of neutralization antibody
date: 2021-09-10
journal: Pediatr Neonatol
DOI: 10.1016/j.pedneo.2021.07.007
sha: 50d114253e48e07631f4883b24d830f7348aaa30
doc_id: 721610
cord_uid: mexw7uhf

nan

Infants/neonates are usually less susceptible to SARS-CoV-2 infection. 1, 2 Like other viral infections such as varicella, the outcome of intrauterine or neonatal infection is strongly correlated with mothers. During the pregnancy, fetuses born to pregnant women with SARS-CoV-2 infection are prone to intrauterine growth restriction, prematurity, or even miscarriage because of maternal placenta insufficiency caused directly by the infection or inflammation. 3 In contrast, neonates may be protected by effective placental antibody transfer if the expectant mother acquired SARS-CoV-2 infection in the late trimester. 4, 5 Here, we describe the serial detection of antibodies and associated neutralizing activity in a mother-neonate pair, in which the mother contracted mild SARS-CoV-2 infection in the third trimester.

A healthy newborn with a gestation age (GA) of 38 weeks and birth bodyweight of 2630 gm was born to a mother who had coronavirus disease 2019 (COVID-19) in the early third trimester (GA = 30 weeks and four days). The mother and newborn were confirmed negative by nasopharyngeal RT-PCR before and after the delivery. Serum samples from the mother before delivery (day 0) and cord blood (child, day 0) were collected. We also obtained sera J o u r n a l P r e -p r o o f from the mother (day 180) and child (days 7, 30, 60, 120, 180) after birth. We used an enzyme-linked immunosorbent assay (ELISA) to evaluate antibodies against the SARS-CoV-2 spike glycoprotein S1, receptor-binding domain (RBD), and nucleocapsid (N) protein (Sino) for these samples and incubated them overnight at 4°C. Each well was blocked with StartingBlock™ T20 blocking buffer (Thermo Fischer Scientific, Waltham, MA, USA).

Samples were added to the wells and incubated for 1 h at 37°C. Horseradish peroxidasetagged anti-human antibodies (IgG, IgM, and IgA, Abcam, Cambridge, UK) were added to the wells for 1 h at 37°C. The chromogenic reagent was 3,3′,5,5′-tetramethylbenzidine (R&D Systems, Minneapolis, MN, USA). In our ELISA method, the cut-off value for the antibody against S1, RBD, and N protein was 0.15, 0.2, and 0.3 (optical density at 450 nm), respectively. A virus neutralization assay with an inhibitory concentration of >99% (IC>99%) was performed to measure the functional antibody titers of these samples at a biosafety level 3 by the protocol described previously. 6, 7 Briefly, Vero E6 cells were seeded in a 96-well plate and incubated at 37°C for 24 h. All sera were heat-inactivated at 56°C for 30 minutes, and then serially diluted twofold with Dulbecco's modified Eagle's medium (Gibco) and 2% fetal bovine serum (Gibco). The 100 50% tissue culture infectious doses (100 TCID50) of SARS-CoV-2 were incubated with a serial dilution of serum at 37°C for 1 h before infection of Vero E6 cells. The infected cells were incubated at 37°C for five days, then fixed with 10% formaldehyde and stained with crystal violet. The neutralizing titer determination is based on J o u r n a l P r e -p r o o f the presence or absence of the cytopathic effect, and then the logarithm of the 50% endpoint is calculated using the Reed-Muench method. Each serum sample was tested in four replicates.

Using an indirect ELISA assay, serum antibody titers of the newborn against S1, RBD, and N protein lasted nearly two months after birth. However, antibodies against S1 and RBD decayed to an undetectable level four months after birth. Regarding the mother, antibodies A live virus neutralization assay was conducted in a biosafety level 3 laboratory to evaluate whether the serum contained neutralizing antibodies (NAbs) to prevent SARS-CoV-titers lasted for two months (Fig. 1D) . These results indicate that serum of the infant born to a SARS-CoV-2-infected mother contained NAbs against SARS-CoV-2, but a decline in the neutralizing antibody response was subsequently observed.

This study demonstrated effective placental antibody transfer in a mother-neonate pair. The placental antibody transfer ratio was around one with the ELISA method. However, the NAb titer determined by the neutralization assay using the wild-type virus was higher in the neonate at birth than the mother. We further confirmed that NAbs could last almost two months in the neonate, suggesting the potential of passive protective immunity for two months, even though the mother had only mild disease. This result is a promising observation for maternal immunization to protect neonates against COVID-19. Vaccine-induced NAb titer is usually stronger than natural infection. 8 This study provides evidence that maternal immunization with the SARS-CoV-2 vaccine may confer protection in neonates for two months or longer. This hypothesis requires more studies for validation in the current vaccine era.

This work was supported by Ministry of Science and Technology (grant MOST 109-2327-B-182-002) and Chang Gung Memorial Hospital (grant CORPG3K0311), Taiwan.

The study was approved by Institutional Review Board, Chang Gung Hospital, Taiwan (202000837A3).

The authors have no conflicts of interest relevant to this article.

Pair. An indirect ELISA based on coating with different viral antigens, including glycoprotein S1 (A), RBD (B), and N protein (C), was used to detect antibodies in serum. A live virus neutralization test was conducted in a biosafety level 3 laboratory to determine the neutralizing antibody titers in the mother and infant (D). Serum samples were from the mother before delivery (day 0), cord blood (child, day 0), and from the mother (day 180) and child (days 7, 30, 60, 120, and 180) after birth.

J o u r n a l P r e -p r o o f

SARS-CoV-2 infection in children: Transmission dynamics and clinical characteristics

Clinical characteristics of novel coronavirus disease 2019 (COVID-19) in newborns, infants and children

Outcomes of neonates born to mothers with severe acute respiratory syndrome coronavirus 2 infection at a large medical center

Assessment of Maternal and Neonatal Cord Blood SARS-CoV-2 Antibodies and Placental Transfer Ratios

Transplacental Antibody Transfer, and Placental Pathology in Pregnancies During the COVID-19 Pandemic

SARS-CoV-2 genomic surveillance in Taiwan revealed novel ORF8-deletion mutant and clade possibly associated with infections in Middle East

Development of CpG-adjuvanted stable prefusion SARS-CoV-2 spike antigen as a subunit vaccine against COVID-19

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial

We thank the study participants who donated their time and samples. We thank Kuan-Ting